Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

NIH Consensus On Hepatitis C Recommends Interferon Alpha NUTLEY, N.J. -- March 26, 1997 -- The National Institutes of Health has convened a consensus conference on chronic hepatitis C infection, concluding that initial therapy of chronic hepatitis C infection should consist of a 12-month regimen of interferon alfa therapy in order to reap the greatest potential benefits of treatment. Hepatitis C currently affects an estimated 4 million Americans and puts them at risk of developing liver cancer and cirrhosis of the liver. Preliminary data presented to the consensus conference panel indicate that interferon alfa therapy is cost-effective, falling well within the range of costs per adjusted-life-year gained of generally accepted therapies (e.g., agents for hypertension). The only interferon alfa labeled for 12 months of treatment is Roche's Roferon(R)-A. Roche recognizes that interferon therapy requires persistence and diligence on the part of both patient and physician to ensure compliance with the treatment regimen. Aware of this need, Roche has joined with the Hepatitis Foundation International to launch a new educational campaign, "C What All the Hep's About: Get the Facts on Hepatitis C." Patients and their families can call the Foundation at 1-800-891-0707. In addition to the consumer campaign, Roche is offering physicians several tools to improve patient compliance with therapy and manage treatment side effects. The package contains a brochure with answers to frequently asked questions about chronic hepatitis C, a Spanish- and English-language video, a quarterly newsletter, and a workbook/diary that helps patients monitor their responses to therapy. The compliance package, "The Roferon(R)-A PATH (Partners Allied in the Treatment of Chronic Hepatitis C) Patient Compliance Kit," can be obtained by calling 1-800-LAROCHE. E-mail this page to a friend or colleague! To print, use this version